论文部分内容阅读
自Subramanian氏于1971年证实~(99m)Tc-三聚磷酸盐骨闪烁照像有临床应用价值以来,~(99m)Tc-磷酸化合物即成为临床上常用的一种骨显像剂。可是,~(99m)Tc-磷酸化合物骨闪烁照像所表现的异常像,缺乏特异性,即不仅骨肿瘤病变可呈现阳性所见,就是一般骨骼病患也可呈现类似改变。因而,1974年Oku-yama氏提出用~(67)Ga-枸橼酸盐,~(99m)Tc-博莱霉素进行骨闪烁照像,并认为其对骨肿瘤诊断有价值。1979年中间氏等提出用氯化~(201)铊闪烁照像来诊断骨骼疾患。但正如奥氏等所说,对于骨肿瘤病变的诊断,不能单纯以骨闪烁照像,而并用肿瘤显像是极为重要的。作者为进一步探讨氯化~(201)铊闪烁照像对骨骼疾患的诊断价值,曾对癌研究会附属医院放射线科收治的疑似有骨骼疾病的88例患者,间隔一个月以内分别
~ (99m) Tc-Phosphate has become a clinically useful bone imaging agent since Subramanian confirmed the clinical value of ~ (99m) Tc-tripolyphosphate bone scintigraphy in 1971. However, the abnormal image of ~ (99m) Tc-phosphate scintigraphy shows a lack of specificity, not only in the presence of bone tumor lesions, but also in normal skeletal patients. Therefore, in 1974, Oku-yama’s proposed bone scintigraphy with ~ (67) Ga-citrate and ~ (99m) Tc-bleomycin and was considered valuable for the diagnosis of bone tumors. In 1979, et al proposed the use of ~ (201) thallium scintigraphy to diagnose skeletal disorders. However, as Ostras said, for the diagnosis of bone tumor lesions, can not simply scintigraphy with bone scintigraphy, and the use of tumor imaging is extremely important. In order to further explore the diagnostic value of ~ (201) thallium scintigraphy for skeletal disorders, 88 patients with suspected skeletal diseases admitted to Department of Radiology, Cancer Research Hospital were separated within one month